FDA Concluded there were "Increased Risks" back in 2001.

"This Medical Reviewer is concluding that there is an increased risk of cardiovascular thrombotic events, particularly myocardial infarction, in the rofecoxib group compared with the naproxen group." [FDA]

See page 34 of Dr. Shari L. Targum's memo (linked above).